Loading organizations...
Huajin Investment, an entity potentially associated with Hong Kong based on its domain, maintains an undisclosed operational focus. Publicly available information regarding its specific business model, target sectors, customer base, and scale:including assets under management, funding raised, or employee count:remains limited, hindering a precise understanding of its role. Furthermore, the organization's portfolio companies, lead investors, or any other recognizable affiliations are similarly not publicly known, obscuring its market presence. Its identity is often conflated with unrelated entities like Central Huijin Investment or Huajin Bureau Holdings due to name similarities. While some records indicate audited financials for a 'Huajin' entity as of December 31, 2022, further specifics about this particular Huajin Investment are unavailable, and the founding year and names of its founders are also not publicly documented.
Huajin Investment has 1 tracked investment across 1 company. The latest tracked deal is $82.1M Series D in Atom Bioscience & Pharmaceutical in October 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 16, 2023 | Atom Bioscience & Pharmaceutical | $82.1M Series D | Kaitai Capital | Fortune Capital |